Previous 10 | Next 10 |
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenc...
Cells of 114-year-old converted to young pluripotent stem cells Evidence of reversal of the telomere aging clock in a supercentenarian Supports hypothesis of no upper age limit for reprogramming cellular aging Introduces possibility of identifying the underlying biolo...
Program will utilize AgeX’s proprietary PureStem ® cell derivation and manufacturing technology platform Goal of developing cellular therapies for Huntington’s disease and potentially Parkinson’s, Alzheimer’s and other neurological conditions Build...
Gainers: Datasea (NASDAQ: DTSS ) +81% . More news on: Datasea Inc., Sintx Technologies, Inc., ReTo Eco-Solutions, Inc., Stocks on the move, , Read more ...
First research collaboration for immunotolerance UniverCyte TM technology platform, marking launch of new business development and collaboration strategy Secures milestone collaboration in Japan, where cell therapy R&D is advancing rapidly in a favourable regulatory and commercial...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that the company will present at the following four conferences this month: Biotech Showcase , January 13-15; Pre...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced the drawdown of a $1.3 million tranche of financing pursuant to its unsecured loan facility from Juvenescence Limited. ...
AgeX Therapeutics, Inc. (NYSE American: AGE) and Lineage Cell Therapeutics, Inc. (NYSE American and TASE LCTX), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled “Methods of Reprogramming Animal Somatic Cells&...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) and AgeX Therapeutics, Inc. (NYSE American: AGE), announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,501,723, entitled “Methods of Reprogramming Animal Somatic Cells...
AgeX Therapeutics , Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, issued a letter to shareholders from Michael D. West, PhD, founder and CEO, and Gregory Bailey, MD, Chairman, reflecting on progre...
News, Short Squeeze, Breakout and More Instantly...
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024 Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the fourth quarter of 2024; IND submission to the FDA for the initiation of a Phas...
ALAMEDA, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended Decembe...
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 211.4% to $0.4422 on volume of 532,901,553 shares Fisker Inc. Class A (FSR) rose 12.8% to $0.1747 on volume of 376,460,729 shares Better Therapeutics Inc. (BTTX) rose 27.4% to $0.0446 on volume...